What is food noise?
Food noise is the popular name for thoughts about food that keep arriving without being asked: what to eat next, whether to eat, what was eaten, when the next meal is. Most people think about food, and that is ordinary. The phrase describes thoughts that feel persistent, intrusive and unwelcome, enough to take up attention and sometimes to distress.
It began as a patient and clinician word, not a medical term. Hayashi and colleagues, writing in Nutrients in 2023, noted anecdotal reports from patients and clinicians of less rumination and preoccupation with food on semaglutide, and set out to ask what the phrase might mean in research terms. Their answer links it to food cue reactivity: how loudly the brain responds when food is seen, smelled or remembered.
How do researchers define and measure it?
A 2025 paper in Nutrition and Diabetes offers a working definition: persistent thoughts about food that the person finds unwanted or distressing and that may cause harm, set apart from routine food thoughts by intensity and intrusiveness, resembling rumination. The same paper says a formal clinical definition and a method of measurement were lacking.
The measuring tool is newer still. The Food Noise Questionnaire, published in Obesity in 2025, has five items and was tested in 400 participants. It showed high internal consistency and good repeatability a week later, and it behaved like existing measures of preoccupation with food. Its authors state that its clinical usefulness still needs study. Commentaries in 2026 go further: the evidence on what food noise is, what causes it and whether it differs from cravings and food preoccupation is limited, and there is a risk of turning a common human experience into a condition.
Why do Mounjaro and Ozempic seem to quieten it?
The trial evidence is on neighbouring outcomes. In a double-blind trial of 72 adults, semaglutide 2.4 mg for 20 weeks cut the amount eaten at a test lunch by 35% and, on the Control of Eating Questionnaire, brought better control of eating and fewer, weaker cravings. In STEP 5, a 104-week trial, craving control stayed better on semaglutide at weeks 20, 52 and 104 in a subgroup of 88 people, though the statistics were not corrected for multiple testing.
For tirzepatide, a six-week phase 1 trial in 114 adults found lower appetite, cravings, tendency to overeat, hunger and reactivity to foods in the environment than placebo. Brain imaging pointed the same way, with lower activation to pictures of high-fat, high-sugar food in several regions, though the combined measure for palatable foods did not reach significance. That fits the idea that the medicines act on appetite and reward signalling, and it remains an interpretation of a short trial.
Surveys add the voice of users. The INFORM survey asked 550 US adults on semaglutide to recall their food noise before starting, and their median questionnaire score fell from 13 to 6 out of 20. It relied on memory, had no comparison group, and its authors work for the manufacturer. Treat it as a survey. How the two medicines compare overall is in the Ozempic and Mounjaro head-to-head article, and how tirzepatide works is in the tirzepatide explainer.
What happens when the medicine stops?
Weight is the part that has been tested. In the STEP 1 extension, 327 people were followed for a year after treatment stopped: those who had been on semaglutide regained 11.6 percentage points of body weight, against 1.9 for those who had been on placebo, about two thirds of what the semaglutide group had lost. In SURMOUNT-4, people switched to placebo after 36 weeks of tirzepatide changed by +14.0% over the next 52 weeks, while those who continued changed by -5.5%. The article on weight after stopping goes through those trials and the real-world data.
Whether the thoughts return is a separate question, and the answer is not in those trials. They measured weight and cardiometabolic markers, not food noise. It would be reasonable to expect appetite to rise as weight returns, and that is an inference, not a finding. The studies cited here do not say how fast, how much, or in whom.
Is food noise an eating disorder?
No. Food noise is a description of an experience that many people recognise, and an eating disorder is a diagnosis made by a clinician. They can overlap. The researchers who proposed a definition note that anecdotes of food noise resemble how people with eating disorders describe their thoughts, and that it may occur in them.
A doctor or psychologist is worth seeing for binge eating, eating very little or skipping meals to control weight, making oneself vomit, using laxatives or exercise to compensate, or food thoughts that come with low mood, anxiety or shame. A review of 25 studies of GLP-1 medicines and eating behaviours found limited data on eating disorders, and for most people eating behaviours improved or stayed the same. A weight-loss medicine is not a treatment for an eating disorder, and the assessment should come first. The side effects article covers what else to plan for.
Who decides, and how are these medicines obtained?
Semaglutide and tirzepatide are prescription-only medicines, used after a full evaluation by a doctor. At this clinic GLP-1 medicines are used only after a full assessment with regular follow-up, within medical weight management. Obtaining them without that review carries its own risks, set out in the article on getting GLP-1 medicines legally in Malaysia, and the wider picture of what helps and what does not is in the slimming treatment overview.
The honest complication
The word is ahead of the science. The questionnaire is new, the definition is a proposal, the trials measured cravings and control of eating, and the best-known food noise numbers come from a recall survey. Quieter food thoughts on a medicine are a real report from real people, and they are not yet a measured outcome of a trial. Whether to use a medicine for any reason is a decision made after assessment.
